Exclusive - EU regulators set to clear $40.5 billion Teva, Allergan deal: sources

BRUSSELS (Reuters) - EU antitrust regulators are set to clear Teva Pharmaceutical Industries' $40.5 billion bid for Allergan's generics unit after the Israeli company agreed to divest some drug products, three people familiar with the matter said on Wednesday.

Teva, the world's biggest generic drugsmaker, will divest some products already on the market and others in the pipeline to address competition concerns by the European Commission, the people said. The package includes drugs from both Teva and Allergan.

Teva will gain bigger economies of scale, a crucial element in the low-margin generic drugs business, with the deal, the largest in Israel's corporate history.

 

(Reporting by Foo Yun Chee, editing by David Evans)